clinical trial · NCT07717892
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
ADHDSolriamfetol Dose ASolriamfetol Dose BPlacebo
brief summary
This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to \<18 years with ADHD.
started
Jun 25, 2026
primary completion
Jun 30, 2028
completion
Jun 30, 2028
last updated
Sep 8, 2026
detailed description
Eligible subjects are adolescents, 12 to \<18 years of age, with a primary diagnosis of ADHD based on criteria established by the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. Subjects will be randomized in a 1:1:1 ratio to receive solriamfetol dose A, solriamfetol dose B or placebo once daily for 6 weeks.
official title
A Phase 3, Randomized, 6-Week, Double-blind, Placebo- Controlled Trial of Solriamfetol in Adolescents Aged 12 to <18 Years With Attention Deficit Hyperactivity Disorder (ADHD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol